Cover Image

Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity

The aim of this retrospective analysis is to estimate the most appropriate single cycle and cumulative doses of 225Ac-DOTATOC in patients treated for somatostatin-receptor-expressing cancers.

Saved in:
Bibliographic Details
Main Authors: Kratochwil, Clemens (Author) , Apostolidis, Leonidas (Author) , Rathke, Hendrik (Author) , Apostolidis, Christos (Author) , Bicu, Felix (Author) , Bruchertseifer, Frank (Author) , Choyke, Peter L. (Author) , Haberkorn, Uwe (Author) , Giesel, Frederik L. (Author) , Morgenstern, Alfred (Author)
Format: Article (Journal)
Language:English
Published: 26 August 2021
In: European journal of nuclear medicine
Year: 2021, Volume: 49, Issue: 1, Pages: 54-63
ISSN:1432-105X
DOI:10.1007/s00259-021-05474-1
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00259-021-05474-1
Get full text
Author Notes:Clemens Kratochwil, Leonidas Apostolidis, Hendrik Rathke, Christos Apostolidis, Felix Bicu, Frank Bruchertseifer, Peter L. Choyke, Uwe Haberkorn, Frederik L. Giesel, Alfred Morgenstern
Description
Summary:The aim of this retrospective analysis is to estimate the most appropriate single cycle and cumulative doses of 225Ac-DOTATOC in patients treated for somatostatin-receptor-expressing cancers.
Item Description:Gesehen am 21.04.2023
Die Zahl 225 im Titel ist hochgestellt
Physical Description:Online Resource
ISSN:1432-105X
DOI:10.1007/s00259-021-05474-1

Similar Items